Subtype
Breast Carcinoma by Gene Expression Profile
CI-CAN-00004666Explore in graph →
537 active trials6 approved drugs101 evidence items
- NCIt
- C53553
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004666Explore in graph →
Clinical trials
1,299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (217)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00791037 | Vaccine Therapy in Treating Patients With Stage IV Breast Cancer | completed | Phase 1 / Phase 2 | 23 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01306032 | Phase II ABT-888 With Cyclophosphamide | completed | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 2 | Apr 26, 2017 | clinicaltrials |
| NCT02567396 |
| Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction |
| withdrawn |
| Phase 1 |
| 0 |
| National Cancer Institute (NCI)NIH |
| 0 |
| Apr 24, 2017 |
| clinicaltrials |
| NCT01151449 | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01729884 | Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer | terminated | Phase 2 | 3 | University of WashingtonOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT02685306 | A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer | withdrawn | Phase 2 | 0 | Peregrine PharmaceuticalsINDUSTRY | 0 | Mar 9, 2017 | clinicaltrials |
| NCT02213744 | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients(HERMIONE) | terminated | Phase 2 / Phase 3 | 113 | Merrimack PharmaceuticalsINDUSTRY | 9 | Jan 6, 2017 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT01451632 | A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers | completed | Phase 1 | 48 | Merrimack PharmaceuticalsINDUSTRY | 1 | Sep 8, 2016 | clinicaltrials |
| NCT02539017 | The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer | withdrawn | Phase 2 | 0 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 26, 2016 | clinicaltrials |
| NCT02511847 | Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib | unknown | Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT01575522 | Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2016 | clinicaltrials |
| NCT00813956 | A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer | completed | Phase 2 | 80 | SanofiINDUSTRY | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01276496 | Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2016 | clinicaltrials |
| NCT02685657 | Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer | unknown | Phase 2 | 164 | Russian Academy of Medical SciencesOTHER | 0 | Feb 22, 2016 | clinicaltrials |
| NCT02681562 | Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients | unknown | Phase 2 | 45 | Istituti Ospitalieri di CremonaOTHER | 0 | Feb 15, 2016 | clinicaltrials |
| NCT02616848 | Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers | unknown | Phase 1 | 1 | Istituti Ospitalieri di CremonaOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT02615457 | Huaier Granule in Treating Women With Triple Negative Breast Cancer | unknown | Phase 4 | 300 | Shandong UniversityOTHER | 1 | Nov 26, 2015 | clinicaltrials |
| NCT01677455 | An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer(Enchant) | completed | Phase 2 | 51 | Synta Pharmaceuticals Corp.INDUSTRY | 8 | Nov 5, 2015 | clinicaltrials |
| NCT02595138 | Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer | unknown | Phase 3 | 430 | Chinese Academy of Medical SciencesOTHER | 0 | Nov 3, 2015 | clinicaltrials |
| NCT02580747 | Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso | unknown | Phase 1 | 20 | Chinese PLA General HospitalOTHER | 1 | Oct 20, 2015 | clinicaltrials |
| NCT01238133 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer | terminated | Phase 1 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2015 | clinicaltrials |
| NCT01281150 | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT01071564 | RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery | terminated | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00951054 | A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 61 | Nippon Kayaku Co., Ltd.INDUSTRY | 1 | Feb 16, 2015 | clinicaltrials |
| NCT01238952 | Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer | completed | Phase 1 | 4 | Nippon Kayaku Co., Ltd.INDUSTRY | 1 | Nov 13, 2014 | clinicaltrials |
| NCT02012634 | Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer(MACRO) | unknown | — | 340 | Xijing HospitalOTHER | 1 | Nov 13, 2014 | clinicaltrials |
| NCT01969032 | Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer | completed | Phase 2 | 41 | Russian Academy of Medical SciencesOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT01245205 | Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Oct 23, 2014 | clinicaltrials |
| NCT00079326 | Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer | terminated | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00077376 | Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer | completed | Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT01329640 | Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01) | terminated | Phase 2 | 9 | Instituto do Cancer do Estado de São PauloOTHER | 1 | May 21, 2014 | clinicaltrials |
| NCT01594177 | Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy(DAFNE) | completed | Phase 2 | 65 | GBG Forschungs GmbHOTHER | 1 | Mar 13, 2014 | clinicaltrials |
| NCT01292083 | Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 0 | Feb 6, 2014 | clinicaltrials |
| NCT01695057 | Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 0 | Jan 28, 2014 | clinicaltrials |
| NCT00006228 | Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01705340 | Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | terminated | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01111175 | Triple Negative Breast Cancer Biomarker Study | completed | — | 14 | US Oncology ResearchINDUSTRY | 1 | Jul 23, 2013 | clinicaltrials |
| NCT00098605 | Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00003440 | Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic | completed | Phase 3 | 580 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT01219907 | Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer | withdrawn | Phase 1 | 0 | University of WashingtonOTHER | 1 | May 17, 2013 | clinicaltrials |
| NCT00039455 | Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer | terminated | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00817362 | Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer | terminated | Phase 2 | 29 | Infinity Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 11, 2012 | clinicaltrials |
| NCT01100489 | Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 8, 2011 | clinicaltrials |
| NCT01276769 | Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer | unknown | Phase 2 | 80 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 16, 2011 | clinicaltrials |
Data updated 22 days agoSource updated May 25, 2017source: clinicaltrials